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The Geisinger Model 
Patrick Walberer 
Despite having one of the highest health expenditures internationally, the US health 
system for many years has only achieved average care outcomes. Additionally, the 
quality of care is not adequately considered in reimbursement processes. Insuffi-
cient individual access to medical care, fragmented care structures, as well as the 
still high number of uninsured Americans, represent great challenges across the na-
tion. Geisinger Health System, an integrated healthcare delivery system located in 
Pennsylvania which has operated for more than 100 years, has set a goal to counter  
sprawling healthcare costs with innovative service, insurance, and remuneration 
structures. Therefore, Geisinger Health System relies in particular on innovations 
in information technology, which are based on an electronic health record system 
that spans all institutions. The approach and implementation of innovations as well 
as some directive innovations of the Geisinger Health System are examined in this 
essay. The value added for the patient as well as for Geisinger will also be discussed. 
Finally, prospects and limitations will be presented to evaluate if and how the inno-
vative thinking of Geisinger Health System can be seen as a beacon for other US 
healthcare providers. 
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1 Status and Hurdles of Health Care Delivery in Rural US Regions 
Historically, there exist various parallel healthcare and insurance systems in the United 
States of America (US) which operate as a "highly inefficient, … extremely fragmented 
whole" (Smith and Medalia, 2014). The insurance coverage of the US population, de-
fined as access to medical care, is a very heterogeneous mixture of mainly private insur-
ance as well as many state support programs, without a general insurance obligation. 
Fee-for-service reimbursement dominates the insurance market, but some plans reward 
good treatment and outcomes (Yuan et al., 2017, pp. 12-14). With costs of $9,403 per-
capita in 2015, the US health care system ranks third most expensive in the world, while 
the treatment quality is only rated as average (World Bank, 2017). Constantly rising 
treatment costs as well as dissatisfaction of the patients with the care they are provided 
causes further problems for the health care system. 
Usually, US healthcare structures consist of various spatially and organisationally sep-
arated outpatient medical practices, emergency services, and inpatient service providers. 
However, this organisation of care structures no longer corresponds to the demands and 
possibilities for patient care in the 21st century. Innovative care models are only very 
slow introduced into healthcare delivery. A well thought-out medical care restructuring 
including innovative supply components is urgently needed (Prince and Graf, 2015, p. 
16). 
All the problems previously mentioned resulted in a loss of value in the healthcare sys-
tem and created the necessity for reorganisation and innovation. This leads to the fol-
lowing research question, which is to be answered within the scope of this paper:  
2 Classification of Legal Background, Basic Conditions, and Necessities 
Access to medical care in the US depends on an individual’s insurance protection 
through an appropriate health plan. As described in the previous chapter1, health insur-
ance in the US means any type of program that is designed to cover and pay for illness 
expenses. This includes privately purchased insurance and government funded insur-
ance (Medicare) or social welfare program (Medicaid) (Shi and Singh, 2013, p.139; 
KFF, 2017; Torgan, 2013).  
Fragmented, uncoordinated, and highly variable treatment procedures can be identified 
within this system. Fragmented healthcare structures often lead to safety risks as well as 
wasted resources, two main reasons for the low value of US healthcare, defined as the 
outcome depending on the cost of the input (Porter and Olmsted-Teisberg, 2006, p. 4). 
The aim of this essay is to examine if and how the Geisinger model can be seen as an 
example for innovative healthcare delivery in the US and describe what generalizable 
implications can be derived from it for other providers. 
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Private health insurance companies, in particular, negotiate health plans with individual 
supply conditions and payment models with different service provider groups, creating 
a lot of bureaucracy and inefficiency (Chua, 2006, p. 4; Torgan, 2013).  
Governmental reform measured previously proposed mostly focused on better access to 
care or cost control of healthcare. Thereby, both approaches ignored the basic problem 
of lower healthcare value for a long time (Porter and Olmsted-Teisberg, 2006, p. 4; Tor-
gan, 2013). It is important to increase the value of healthcare and maximize the benefits 
of high healthcare expenditures. Productivity and efficiency gains, which are common 
in other industrial sectors, barely exist or are non-existent in the US healthcare sector 
(Paulus et al., 2008, p. 1,235). To increase the value of healthcare, a well-thought-out 
health care system strategy as well as the associated organisational capacity to change 
is needed. Sustainable healthcare value can only be created when the various stages of 
the care process are abolished, automated, delegated to appropriate but more cost-effec-
tive personnel, or otherwise made more efficient (Porter and Olmsted-Teisberg, 2006, 
pp. 4-6; Torgan, 2013). 
Key components for an innovative change in care processes are:  
 Consumers and patients who are actively directed to behaviour that alleviates ill-
nesses or increases the patient-centred performance. 
 Safer and more effective medicines or medical devices are used 
 Physicians who provide faster, more appropriate and reliable patient-centred care 
 Costs of the supply chains are systematically reduced and the value of healthcare 
increased 
These changes offer the greatest sustainability within a supply system, in which the fo-
cus is on the creation of value and the output of innovation is measured and appropriately 
rewarded in the market (Porter and Teisberg, 2006, pp. 4-6; Paulus et al., 2008, pp. 
1,235-1,236). 
The US healthcare system is not just struggling with the existing lack of value; it also 
has geographical barriers. The geography and settlement structure can be characterized 
by a two-track development - various metropolises of millions and many sparsely pop-
ulated rural regions. The organisation and assurance of an adequate supply structure, 
especially in rural areas, is often challenging. This is also the case for Pennsylvania, a 
state in the northeast of the USA with an area of about 120,000 km2 and a population of 
12,702,379. This corresponds to an average population of 106 inhabitants per km2. The 
median age is 39.6 years, with an age cohort between 18 and 64 years comprising 62.3% 
of the population. The number of men and women are almost equal. The Geisinger 
Healthcare System (GHS), headquartered in Danville, Pennsylvania, is predominantly 
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active in Pennsylvania and is therefore subject to the issues in design of its care structure 
described above, especially since the system services rural regions. 
3 Geisinger Healthcare System as an Innovator of Need-based Healthcare 
in the USA 
3.1 Historical background, Ideas, and Development of the GHS 
More than 100 years ago, in 1915, Abigail Geisinger founded her own hospital modelled 
on the Mayo Clinic in rural Pennsylvania and set a mission "to make it the best" (Paulus 
et al., 2008, p. 1,236). Today, this single hospital has developed into its own healthcare 
system consisting of around 30,000 employees, distributed into three hospitals and 110 
network-clinics allocated over 45 counties in Pennsylvania (GHS, 2015, p. 17; Paulus, 
2009, p. 123; O´Connell, 2016). The primary care physicians in the 45 mostly rural 
counties ensure the basic outpatient care of GHS patients in spoke facilities1 and func-
tion as gatekeepers for the downstream and inpatient GHS care provider structures. In 
these downstream care settings, specialists treat patients who have been recommended 
to be seen by a specialist within three hospitals, which act as hubs2 (McKinley et al., 
2002, pp. 574-575).  
 The GHS works as a not-for-profit provider of care in Pennsylvania. The reason GHS 
places importance on offering innovative healthcare solutions is an established culture 
of reinvesting a large amount of their profit every year. In 2016, GHS spent 15% of their 
operating expenses on community support. This amount of community service is three 
times greater than the necessary amount to meet the standards of a charitable organisa-
tion in Pennsylvania. Compared to for-profit organisations, which focus on maximizing 
their revenue and potentially neglect the quality of care, the GHS mission is to develop 
a care model based on innovation and value to enhance the quality of care. Because of 
its clinical and financial success, the not-for-profit mission of GHS is a model for other 
healthcare organisations nationwide (GHS, 2017).  
The GHS was initially an integrated healthcare delivery system3 (IDS) and later devel-
oped into a HMO with central and north-eastern Pennsylvania as the main area of activ-
ity4  (Paulus et al., 2008, pp. 1,236-1,237). As an HMO, the GHS offers four main types 
                                              
1 Spokes are to be understood as facilities for the provision of health services, which serve as the first 
point of contact in the treatment of patients (Porter and Olmsted-Teisberg, 2006, p.197; McKinley et al., 
2002, pp. 574-575). 
2 Hubs are large and centralized health care provider facilities (Porter, Olmsted-Teisberg, 2006, p.197; 
McKinley et al., 2002, pp. 574-575). 
3 An IDS is a network of healthcare organisations where physicians network with or without hospitals 
(Evashwick and Meadors, 1994). 
4 A health maintenance organization (HMO) is a provider for health services as well as a medical insur-
ance group that offers health plans (Kovner and Knickman, 2011, p.31). 
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of health plans: one for children, a plan for individuals and families, a plan specific to 
Medicare recipients, and separate plan for Medicaid recipients (Geisinger, 2017). In 
2015, the Geisinger Health Plans (GHP) had 540,172 members, of which approximately 
31% were on the Medicaid plan. A total of over 2,640,000 ambulatory patients were 
seen and over 213,000 patients were treated in the emergency room (GHS 2015). The 
referrals to GHS facilities are not limited to GHS doctors, but can also be made by doc-
tors outside the GHS (Paulus et al., 2008, pp. 1,236-1,237). With a volume of 33% of 
the GHS total turnover, the proportion of treated GHP patients is significantly lower 
than non-GHP patient population (Paulus et al., 2008, p. 1,236). This figure demon-
strates that recommendations for patients from outside providers are important to the 
success of GHS (Paulus et al., 2008, pp. 1,236-1,237). 
The GHS can particularly be characterized by its strong affinity toward and focus on 
improving healthcare delivery. In order to design innovative insurance and reimburse-
ment models, the GHS has always been ready to take risks, believing in the future suc-
cess of the projects. Their conviction in high-value treatment quality is particularly clear 
since Geisinger started to offer a reimbursement of costs a few years ago to patients who 
were not satisfied with their treatment (Burke, 2017; Casale et al., 2007, pp. 613-623).  
Geisinger´s decision to take part in the Medicaid managed care program required –es-
pecially for the rural areas of Pennsylvania – a suitable and cost-effective strategy for 
treatment options for patients living in these regions. This was the starting point of an 
innovative care model, for which e-visits and telemedicine based expert consultations 
were actively researched (Prince and Graf, 2015, p. 16). Geisinger's understanding of 
how healthcare is provided is subject to rapid change in treatment options, remuneration 
models, and communication technologies particularly influenced by demographic 
changes. Geisinger's strength as a participant in healthcare delivery is that it can effec-
tively adapt to these trends and other conditions. To deliver healthcare that patients need 
most, GHS has tested various care models, focusing on innovations in the medical, in-
surance, and technological context. GHS has continually improved these models 
through adaptations and further developments over time. Furthermore, this positive and 
innovative image as a healthcare supplier can play a crucial role as a competitive pa-
rameter (Prince and Graf, 2015, p. 16; Housley, 2011).  
3.2 Understanding the Systematic Implementation of Innovation at 
Geisinger 
To understand GHS´s insight and passion for innovation, it is important to take a closer 
look at its historically justified guiding culture and principles. The development and 
implementation of innovation is a very labour intensive undertaking, according to 
Geisinger. Many other healthcare providers simply add innovative concepts to existing 
processes. For further development and implementation of GHS´s supply and financing 
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structures, it is essential to place this task in the hands of an inter-professional team. 
Such a team at GHS, especially in the case of large innovation projects, consists of GHS 
employees of different professions, for example clinicians, operators, controllers, pay-
ers, and, increasingly, also patients or customers. This team is expected to first assess 
changes in the patient care and disease spectrum, evaluate the required and available 
technologies, and examine existing insurance and reimbursement structures. Even 
though the team members all belong to the same healthcare system, each has their own 
viewpoint, motivation, and goals. In addition, the group is striving at the beginning of 
each innovation process for an answer to a simple yet rarely asked question: Which 
realistically viable care model5 can most reliably deliver the highest value of health care? 
Subsequently, there is a continuous search for new options for insurance, reimburse-
ment, and healthcare models to be added to the GHS. This ability to assess and respond 
adequately to the changes that underlie different inputs is a very important element for 
future success in GHS´s opinion (Prince and Graf, 2015, p. 16; Paulus et al., 2008, p. 
1,237). 
Prior to designing a new care model, a clinical business plan is developed that includes 
the expected outcomes based on the appropriate processes, outcome measurements, and 
management responsibilities for each implementation step. The development teams are 
supported by clinical evidence of existing workflows, analyses of financial reimburse-
ment policies, and legal frameworks. To redesign specific supply and reimbursement 
models, Geisinger pays particular attention to the following four areas:  
- Service providers with the greatest impact on the patient population or resource 
consumption  
- Services with the greatest degree of unauthorized variations  
- Models with evidence-based or consistently derived best-practice and easily acces-
sible outcome measurements  
- Healthcare services with the highest expected diversity in outcome performance  
In addition, GHS managers are particularly focused on initiatives that are expected to 
have a noticeable effect on the healthcare system as soon as possible. Newly designed 
supply processes are linked directly to expected efficiency and quality goals. After com-
pletion of the new approach to clinical care, the reimbursement, incentive structures, 
and non-financial remuneration are negotiated between managers of the service provider 
units and GHP executives (Paulus et al., 2008, p. 1,238). 
                                              
5 In this context, the care model is defined as a step-by-step approach, personalized to provide preventive 
care as well as diagnoses, treatments, management, and involvement of ill patients resulting in increased 
value (Paulus et al., 2008, p. 1,237). 
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For the introductory stage of innovation projects GHS usually tries to address the "sweet 
spot”, the one-third of the patients with a GHP for whom Geisinger is financially re-
sponsible as well as their primary medical service provider. These innovations are not 
kept from the other two-thirds of GHS´s patient group, but this approach makes it easier 
for Geisinger to measure the impact of the innovation on the medical as well as on the 
financial aspects of healthcare. Particularly in the case of new GHP reimbursement mod-
els, GHS service providers are given the opportunity to experiment extensively on 
whether new interventions have the potential to develop commercial market models for 
quality and value-based care. As a marketing aspect for any GHP, only patients with a 
GHP enjoy the privilege of being the first to benefit from such innovations (Paulus et 
al., 2008, p. 1,237; Stock et al., 2014, pp. 1,540-1,548). 
To evaluate the innovative approaches and create measurement data for ongoing process 
improvements, Geisinger relies on scientifically recognized methodologies, which in-
clude continuous quality improvements, six-sigma, or lean restructuring. These meth-
odologies examine the influence of the approaches on the healthcare supply and also 
show potential for further improvement for subsequent innovation efforts. This system-
atic approach to developing, introducing, and evaluating innovations at the same time 
allows GHS to create a culture of self-learning and draw conclusions from its own set-
backs for future projects. To that end, the members of the innovation team build modular 
innovation components which can be utilized to further develop functions, technologies, 
or components of already successfully established healthcare supply models at every 
stage of development. Such reusable innovation model components, for example, con-
sist of the use of human resources, hardware and software tools, technologies, or analy-
sis instruments. In addition, this approach and the use of modular innovation compo-
nents allows the GHS to design future supply models faster, creating an optimized and 
cost-effective process. (Paulus et al., 2008, p. 1,238). Previous experience associated 
with the GHS innovation culture shows that the failure rate of innovation projects has 
declined since the introduction of this procedure, and the share of expectations that have 
been reached or even surpassed has risen. This process of scientifically supervised and 
evaluated innovation is repeated over and over again, and thereby plays a decisive part 
in increasing the production of value in the healthcare system (Paulus et al., 2008, p. 
1,238). 
In 2013, the GHS launched a new business unit called Geisinger Ventures (GV), whose 
task is to improve the introduction and growth of new business areas as an extension of 
existing structures in healthcare. Up to now, GV has been supporting the implementation 
of different retail clinic6 model projects in various organizational forms. These GHS 
                                              
6 Retail clinics or micro clinics are small primary care facilities, staffed by nurse practitioners or un-
manned through use of telemedicine applications (Dunn, 2014). 
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retail clinics exists as a number of walk-in business model facilities, including in-store 
clinics, stand-alone retail clinic sites, and combined models with basic healthcare prac-
tices and emergency services at the same site. For each model, various benefits and 
challenges arose in terms of patient care, marketing, personnel composition, and clinical 
integration. However, this was effectively countered by GV through the ability to access 
various modular innovation components and the efforts to create innovative supply mod-
els which can be continually optimized (Prince and Graf, 2015, p. 16). 
3.3 Milestone Innovation Examples from Geisinger Healthcare System 
The following examples illustrate pioneering innovations of GHS.  
In 1995, the platform for an electronic health record (EHR), which covered the complete 
array of outpatient services, was introduced. Today, all inpatient facilities have fully 
implemented integrated EHRs in place (Paulus et al., 2008, p. 1,237). The approach of 
the Geisinger-EHR is innovative in that physicians who are not part of the GHS, but are 
involved in the treatment process of a GHS patient, receive reading and writing author-
ization via a web portal. Even patients can access their own data via the web portal 
online, albeit to a limited extent. This gives patients direct access to their data and helps 
them to become partners within the care system. Providing patients digital tools within 
the EHR enables them to better manage their own care and improve the value of treat-
ment given (Paulus et al., 2008, pp. 1,244-1,245). Geisinger has also aided in the imple-
mentation of integrated electronic systems and centralization of innovation and quality 
support in many freestanding medical practices and small independent hospitals. This 
approach divides the best practices of GHS into individual care process steps and inte-
grates these steps into decision support and other tools that are designed to help deliver 
performance at the right place and at the right time (Paulus et al., 2008, pp. 1,244-1,245). 
GHS´s innovative and transparent culture of digital data workflows and the integrated 
EHR infrastructure within the healthcare system also enable a strategic analysis of long-
term, comparable supply data. In addition, this digital data and workflow make it possi-
ble to provide most of the services with high value near to the patient, minimizing long 
trips for the patient to treatment hubs (Paulus et al., 2008, p. 1,237).  
In 2007, Geisinger launched the community health initiative called MyCode. MyCode 
is a system-wide genomic biobanking program and a platform for value-based precise 
medicine. It links DNA-samples and EHR data for broad research use, particularly pro-
jects focused on learning more about DNA and patient outcomes. The DNA-samples are 
used to generate molecular data, including a comprehensive genotype and exome se-
quence data. Key elements for MyCode are the stable patient population, EHR infra-
structure, and the integrated health system. MyCode is free for all GHS patients and is 
also open to primary care and emergency patients. More than 90,000 people now partic-
ipate in MyCode, with an additional average enrolment rate of 4,000 people per month 
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and consent rate of about 85%. Compared to traditional clinical research approaches, 
the MyCode model is more flexible, faster and more cost-effective. Because the model 
is nearly unlimited in scale, it can be adapted across multiple platforms to create and use 
an even broader range of data with growing resources. MyCode and genomic medicine 
is seen to have the potential for disruptive innovation. Furthermore, the value of 
healthcare can be increased using this kind of precise medicine. Mycode underscores 
the importance of an EHR, because without the underlying EHR infrastructure this in-
novative model of healthcare is not able to work (Carey et al., 2016, pp. 906-913; 
Avellino et al., 2013, pp. 151-152; Faucett and Davis, 2016, pp. 33-35; Wade et al., 
2014, pp. 112-116). The complete and integrated EHR at Geisinger enabled more than 
MyCode; it also paved the way for one of the latest innovations positively influencing 
healthcare delivery - the use of big data technologies in a clinical context (Cohen, 2017).  
Innovative, analytical big data technologies are already used successfully in many 
branches of industry worldwide. However, the breakthrough of this technology-based 
analysis methodology, which processes and systematically uses large, unstructured, and 
digitally collected data packages, is still largely absent in healthcare, despite the large 
amount of digital health data which are collected every day (Dedic and Stanier, 2017). 
The main obstacles to this breakthrough are data protection concerns, legal restrictions, 
as well as a lack of technical possibilities or internally available knowledge (Erskine et. 
al., 2016; Cohen, 2017). A basic prerequisite for the use of big data analysis at GHS was 
the complete conversion to electronic data collection, storage, and use in the form of an 
integrated EHR in 1996, as described at the beginning of this section. To structure the 
collected data and to make it strategically usable, a multi-stage innovation process 
within the EHR was needed, which required the definition of standards for all process 
steps. The lack of uniform standards and lack of compatibility of individual information 
systems are the biggest obstacles for most hospitals seeking to implement big data tech-
nologies.  
In 2015, GHS introduced an IT system called Unified Data Architecture (UDA). The 
UDA can import the huge amounts of data into the data analysis and management sys-
tems already present at GHS. The synthesis of the data enables Geisinger to not only 
record the outcome parameters of their patients, but also evaluate them in a structured 
manner and derive conclusions or patterns from them. Furthermore, a correlation be-
tween the clinical care data and the genomic sequences of individual patients from My-
Code can be established, as well as the visualization of health data on patient cohorts 
and care provider networks (Erskine et al., 2016; Cohen, 2017).  
The data gathered and stored by GHS, for example from clinical department systems 
such as radiology, patient satisfaction surveys, and data from various health-related 
apps, enable Geisinger to create detailed long-term reports of their patients. However, 
Geisinger's Big Data usage strategy is not limited to the data collected individually in 
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its institutions. Rather, with the patient´s prior consent, Geisinger tries to incorporate 
health-related data from outside sources into the UDA. These include, for example, data 
from grocery shopping and loyalty programs from various traders, as well as smartphone 
and app data. The UDA offers each patient extra storage space and has designed soft-
ware to ensure that the addition and storage of data is very easy. With the UDA, 
Geisinger pursues the goal of closing the gap between data, which are digitally collected 
and stored in many areas of life, but are not systematically and structurally linked to 
each other. This is a common challenge for conventional health data systems. Processing 
large amounts of data and importing them from a variety of sources is no longer a prob-
lem for GHS, making it a unique system (Erskine et al., 2016). At present, Geisinger has 
the largest big data application in health care with the UDA. (Erskine et al., 2016).  
4 Geisinger Health System as a Beacon for Change in US Healthcare 
Geisinger Healthcare System is an innovative microcosm in national healthcare which 
can serve as an example for other systems. Their willingness to continue ongoing devel-
opment of healthcare delivery and insurance structures centred on the 21st century pa-
tient´s needs makes it an exceptionally innovative US healthcare provider system. Parts 
of Geisinger´s approaches for offering health-insurance plans as well as delivering 
healthcare are unique and influence decision-makers of other health plans and organiza-
tions (Paulus, 2009). Its health plans, reimbursement structures, and, especially, its focus 
on innovation and value-based treatments are a beacon for change in US healthcare. As 
described in the previous sections, two central ideas can be derived from Geisinger's 
experience in innovation to solve the initially described problems in US healthcare de-
livery and possibly effect national health policy (Robeznieks, 2015). 
Develop and align incentives and reimbursement structures toward value for the patient 
to improve experience and generate financial success  
Geisinger´s integrated health system is both a service provider system and an insurance 
provider. For its GHP patients, it can offer better incentive structures, as opposed to 
other traditional health care provider organisations. Because of its innovative care mod-
els and its financial success, it is easier for GHS to use monetary and non-monetary 
incentives to attract physicians. The ability to cross-subsidize unprofitable services is 
another advantage of the GHS. Even offering patients the right to reclaim payments for 
treatment if they are unsatisfied is an attractive marketing strategy (Paulus and Steele, 
2008, pp. 1,243-1,244; Casale et al., 2007, pp. 613-620). Beside the innovative incentive 
and reimbursement structures, the digital-based business models are also important as-
pects of GHS´s pioneering role in healthcare delivery.  
Digital-based business models and infrastructure are essential to create sustainable 
changes in healthcare provision:  
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The central element of nearly all GHS technological innovations is based on the inte-
grated use of EHR and the associated digital data workflow infrastructure. This helps to 
automate care processes, overcome geographical barriers, involve patients more closely 
in the treatment process, and increase overall safety and healthcare value. Many of the 
current political discussions in the US suggest that EHRs can fundamentally change 
health care provision. According to the evidence gathered at Geisinger, there are indi-
cations that no fundamental change can be expected from the introduction of an her 
alone, but this can be the starting point of a long-term digital change, and thus funda-
mentally change way in which health services are provided. Nevertheless, there are some 
barriers, such as prohibitive implementation costs and low acceptance of EHR technol-
ogy in some areas, as well as the need for stable patient populations. The local applica-
bility and use of EHR technology can be difficult if these requirements are not met.  
These lessons from GHS have the ability to guide other health organizations and insur-
ance providers towards healthcare which is value-based and beneficial to patients as well 
as future innovation. Putting these ideas into action through US policy could dramati-
cally change not only Medicare and Medicaid programs, but transform the entire health 
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